Find an expert

Conserving biodiversity is essential for maintaining the health of the environment upon which human life and wellbeing relies. But the task will only get harder, with human pressures increasing in magnitude and ubiquity. My research tackles questions central to this challenge. A particular focus is biodiversity net gain policy, particularly the design and consequences of biodiversity offsetting, as well as the conservation and restoration of Australia’s woodlands and woodland bird assemblages. I collaborate with a broad network of individuals and organisations including government and non-government bodies to help achieve effective uptake of research findings into policy and environmental management. Sound conservation policy is essential if we are to apply ecological knowledge to reduce and ultimately halt biodiversity declines. I provide guidance on offset/no net loss/net gain policy development internationally including in Malaysia, the UK, Mozambique, and Guinea, and to intergovernmental convening bodies including IPBES, the UN Convention to Combat Desertification, the Convention on Biological Diversity, and the IUCN. I currently chair the IUCN’s Impact Mitigation and Ecological Compensation Thematic Group, am a director of BirdLife Australia and the Australian Wildlife Conservancy, and am a member of the Wentworth Group of Concerned Scientists and The Biodiversity Council. My research group is part of the Centre for Biodiversity & Conservation Science.

Dr Jeanne Marshall is a speech pathologist with expertise in paediatric feeding and swallowing. She is currently employed in a conjoint role between Children's Health Queensland Hospital and Health Service and The University of Queensland. Jeanne’s primary research interest is paediatric feeding disorder, with a particular focus on preventative health in this area. Jeanne has various projects aligned with this concept, across the themes of better diagnostics, early intervention, and awareness and advocacy. Jeanne also has a passion for research translation and building research capacity in the health workforce, working alongside clinicians at Children's Health Queensland to improve care on the front line.

Work Profile: Dr Jeanne Marshall is a Conjoint Senior Research Fellow in speech pathology and an advanced speech pathologist at the Queensland Children's Hospital.

Teaching Themes: Paediatric dysphagia, research methodology, research translation

Research interests: Paediatric Feeding Disorder (PFD); paediatric dysphagia, paediatric trachestomy, complex medical infants and children

Publications: 44 peer-reviewed journal articles and 2 invited editorials. Impact: 412 citations, H-index = 12, average citations per paper = 14.2, field weighted citation impact = 1.61 (2024) (Scopus, May 2025).

Reviewer: International Journal of Speech-Language Pathology; Journal of Paediatrics and Child Health; American Journal of Speech-Language Pathology; Dysphagia; Nutrients

Editorial Boards: Associate Editor for Speech, Language and Hearing

Professional Memberships: Speech Pathology Australia; American Speech Hearing Association International Affiliate

Dr. Helen Marshall is an acclaimed writer, editor and book historian. Her first collection of fiction, Hair Side, Flesh Side, takes its name from the two sides of a piece of parchment—animal skin scraped, stretched and prepared to hold writing. Gifts for the One Who Comes After, her second collection, borrows tropes from the Gothic tradition to negotiate issues of legacy and tradition. Collectively, her two books of short stories have won the World Fantasy Award, the British Fantasy Award, and the Shirley Jackson Award for outstanding achievement in the literature of psychological suspense, horror and the dark fantastic.

Her research as both as a creative practitioner and a scholar emerges out of the recent interest in “weird” fiction, a sub-genre of fantasy which blends supernatural, mythical, and scientific writing. Using modern theories of cognition, my work posits weird texts as “emotion machine[s]” (Tan 1996) designed to defamiliarize traumatic experiences so they can be more easily managed. Her debut novel The Migration (Random House Canada/Titan UK, 2019) exemplifies this. It finds parallels between the emergence of the Black Death in the fourteenth century and the ecological crises of the twenty-first century—that is, periods when humanity has had to confront the possibility of widescale loss of life. What interests her about the topic is not its bleakness but its interrogation of how change might take place, particularly for young people. The Migration explores these challenges. It initially presents metamorphosis as a major crisis, terrifying in its transfiguration of death. But, as the novel progresses, it shows the potential for hopeful and radical change.

Over the last five years notions of the apocalypse have emerged as a theme in her work. Her second collection, Gifts for the One Who Comes After addressed the shaping and persistence of memory in the wake of dangerous upheaval. Rather than taking the long view of history in my first collection, it negotiated very personal issues of legacy and tradition, creating myth-infused worlds where “love is as liable to cut as to cradle, childhood is a supernatural minefield, and death is ‘the slow undoing of beautiful things’” (Quill & Quire, starred review). Likewise her most recent edited collection The Year’s Best Weird Fiction argues that the techniques of defamiliarization used by contemporary authors such as Jeff VanderMeer and China Miéville offer routes for engaging in an increasingly destabilized world.

As a creative practitioner she has worked with interdisciplinary teams using narrative skills, worldbuilding and gamification for the UK’s Ministry of Defence (future threat prediction), the Diamantina Institute (storytelling and empathy for medical researchers), CERN, the European Organization for Nuclear Research (future technologies), and the Department of Defence (innovation and AI – funded $260,000). She has led international workshops to research how creative skills might be applied to wicked problems and she has led a project to apply these skills to technology foresight for the Defence Science Technology Group (Web 3.0 - funded $89,097).

She has further interests in both modern and medieval publishing cultures. Her PhD examined the codicology and palaeography of late medieval manuscripts from England, looking at how Middle English “bestsellers” such as Chaucer’s Canterbury Tales and the anonymous Prick of Conscience made use of traceable networks of production and dissemination. This work builds upon the practical experience she gained working in the publishing industry as the Managing Editor for ChiZine Publications, Canada’s largest independent genre press, where she was involved in all aspects of production including editing, marketing and business management. In 2016 she undertook a research project to investigate the publishing history of Stephen King’s Carrie (1974), which provided a snapshot of the changing social, economic and cultural environment of the publishing industry when key editorial and marketing decisions fashioned the King brand.

Her current projects explore worldbuilding, franchise writing, and the application of creative arts methodologies for interdisciplinary and transdisciplinary ideation.

Dr Henry Marshall is a Thoracic Physician at The Prince Charles Hospital and University of Queensland Thoracic Research Centre. Dr Marshall's research interests are in lung cancer screening/early detection and smoking cessation. His PhD (UQ 2015) was based on the first trial of lung cancer screening in Australia. He is site PI for Australia's second screening trial, the International Lung Screen Trial.

I am Director of Centre for Policy Futures and Coordinator for the Queensland Decarbonisation Hub. Previously I was the Deputy Executive Dean of the Faculty of Humanities, Arts and Social Sciences, a former Head of School for the School of Social Science and Acting Associate Dean Research. My research interests include work and employment, poverty and economic security and the social dimensions of climate change. I am a Fellow of the Academy of the Social Sciences in Australia, and was a member of the ARC College of Experts from 2014-2016. Prior to entering academy I worked in the non-profit sector at the state, national and international level. I am the Australian representative for the Basic Income Earth Network.

Jenny Martin trained as a pharmacist at the Victorian College of Pharmacy (VCP), where she was awarded the Gold Medal for top student over the BPharm course. After completing an MPharm in computational chemistry at the College, Jenny moved to Oxford University for a PhD by research in protein crystallography and drug design. Her DPhil was supported by a prestigious 1851 Science Research Scholarship and several other competitive scholarships. Jenny then undertook two years of postdoctoral research at Rockefeller University in New York, before returning to Australia in 1993 to establish the first protein crystallography laboratory in Queensland. Since then, she has held ARC QEII, ARC Professorial and NHMRC Fellowships and is currently an ARC Australian Laureate Fellow at the Institute for Molecular Bioscience, University of Queensland. Jenny is the recipient of many honours including the ASBMB Roche Medal, the Queensland Smart Women Smart State Research Scientist award, and the Women in Biotech Outstanding Outstanding Biotechnology Achievement Award.

Richard is a cultural anthropologist in the School of Social Science at UQ. His research focuses on Indigenous land rights and native title, cultural heritage, Australian anthropology, and Australian history and culture.

Richard has a PhD in social and cultural studies from The University of Western Australia. His PhD research examined relations between Indigenous and non-Indigenous people in the remote Gulf Country of northern Australia, where he began fieldwork in 2007. After completing his PhD in 2012, Richard has continued to work in the Gulf Country on a range of academic and applied research projects, continuing to develop friendships and collaborations with Indigenous and non-Indigenous people across this area.

Since joining UQ in 2012, Richard has published a range of scholarly articles in leading academic journals as well as the book, The Gulf Country: The story of people and place in outback Queensland (Allen & Unwin, 2019). He has also carried out extensive applied research with Indigenous people on native title claims and cultural heritage matters across Australia, and given expert evidence in the Federal Court of Australia.

I am a clinician researcher with experience in health services research, transdisciplinary care, stroke research, implementation science, and consumer engagement. I am passionate about optimising healthcare services and improving patient care by identifying and addressing inefficiencies using innovative models of care and solutions. I am an expert in the field of transdisciplinary healthcare models.

I am also an occupational therapist with over 8 years of experience in direct patient care across multiple hospital settings, including acute stroke, neuroscience, general medical, orthopaedics, and surgical. I currently work as a Service Improvement and Innovation Officer for community healthcare services at Mater at Home.

Professor Darren Martin FTSE

A Translational Materials Scientist and Intensive Connector, Darren's work sits at the nexus of three key themes of strong fundamental materials science, safe biomaterials and nanomaterials and scalable advanced manufacturing

Darren has always had a strong passion for translation, as evidenced by the following four major research translation outputs, which share the capacity of advanced materials to enable impacts in health, sustainability, and social empowerment:

1996-2012 - Aortech Biomaterials Ltd: We developed a more biostable pacemaker lead insulation which is now implanted in over 80 million people worldwide (Abbott Medical).

2001-2020 - TenasiTech Pty Ltd: In 2020 our scratch resistant and break-proof acrylic glass technology was sold to RTP, a multinational plastics compounder who now sell into several large markets (appliances, personal care, construction, cell phone cases, automotive parts, etc).

2011-2022 - Spinifex Nanocellulose Platform Technology: In 2021, this technology was licensed to Brisbane startup Trioda Medical Pty Ltd for the development of injectable medical gels.

2015-Present - Sorghum-derived Microfibrillated Cellulose (MFC): My team have demonstrated that sorghum grasses can be pulped and refined into MFC in a far more sustainable manner than wood biomass.

International Collaborators and Industry Partners

Professor Martin’s current international collaborators include Stony Brook University (USA), DTU (Denmark) and IIT-Delhi (India). He also has several materials co-development projects and collaborations with companies such as Advanta Seeds, GSA Innovation, Opal Paper, Cardia Bioplastics, GMG, GrapheneX, Duromer, OPS, Dulux, Australian Wood Fibre and others.

Prizes, Honours and Awards

Excellence & Commercialisation

• 2020 - UTS Chancellor’s Award (awarded to the top Alumni from the whole of UTS each year)

• 2020 - UTS Alumni Award for Excellence - Faculty of Science • 2016 & 2019 - 2 UQ Partners in Research Excellence Awards (PIREAs) (Spinifex project Bulugudu partnership)

• 2015 - State finalist in the 2015 Telstra Business Awards (TenasiTech Pty Ltd)

• 2010 - UQ Faculty of Engineering, Architecture and Information Technology Commercialisation Award

• 2010 - Engineers Australia Nanoengineering Panel

• 2007 - iLab Prize at the QLD Enterprise Awards (lead to TenasiTech pre-seed investment from UniSeed)

Service & Leadership

• 2021 - ATSE Reconciliation Action Plan reference group and Industry and Innovation Forum

• 2021 - ATSE President Nominations and Interview Committee to deliberate on the current ATSE President

• 2019 - UQ Teams Leadership Award (Spinifex project Bulugudu partnership)

• 2019 - Business Higher Education Round Table Award (Community Engagement Bulugudu partnership)

• 1993 - Member of the Royal Australian Chemical Institute RACI and the RACI QLD Polymer Group

I am a sport scientist with a background in exercise physiology who has focused on applying cutting-edge science and technology to improve human performance, healthspan, and high-performance systems. My work bridges elite sport, health span, and application of sport technology.

With over 30 years of experience across Olympic sport, professional teams, and health technology startups, I specialise in designing high-performance environments that integrate science, coaching, and technology to drive measurable results.

Core expertise and keywords:

• High-performance sport and human performance

• Sport science and exercise physiology

• Wearable technology and data analytics

• Healthspan optimization and longevity

• Talent identification and performance systems

• Innovation strategy and multidisciplinary teams

I currently hold a conjoint role with the University of Queensland and the Queensland Academy of Sport where I am the Head of the Research and Innovation Unit. Prior to arriving at the University of Queensland, I worked as the Chief Scientist and Director of Performance for a Silicon Valley performance health science start-up company.

Previously, I held leadership roles with the Philadelphia 76ers (Director of Performance) and the Australian Institute of Sport (Senior Sport Scientist), supporting Olympic and professional athletes through applied research, technology integration, and high-performance team design.

My work connects research with real-world impact, supporting athletes, executives, and organizations seeking a competitive edge through science-driven performance and health innovation.

Andrew Martin is inaugural Professor of Innovative Clinical Trials and leads the University of Queensland’s cLinical Trials cApability (ULTRA) program. Andrew was Professor in the biostatistics group at the NHMRC Clinical Trials Centre University of Sydney. He maintains that role in an honorary capacity since joining UQ. Prior to academia, Andrew held senior biostatistics roles within research-based pharmaceutical organisations (Pfizer and Roche).

orcid ID: 0000-0001-5804-2295

Scopus Author ID: 57223730436

Grants

Category 1: $14.3M Category 3: $131.8M

Grants: 2023 Clinical Trials and Cohort Studies Grant ID 2032441 ($1,362,000): P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours; 2022 NHMRC Partnership Projects Grant 2015773 ($1,166,592): Strengthening healthcare systems with Patient Reported Outcome Measures (PROMs); 2020 CA ($600,000): Immuno-metabolic biomarkers for metastatic prostate cancer treatment response; 2018 MRFF Grant APP1170066 ($1,596,631): WHEAT Study on reducing NEC in preterm infants; 2018 CA Grant APP1158397 ($479,375): SCORE trial for shared colorectal cancer care; 2018 CA Grant APP1159837 ($600,000): P3BEP Trial for advanced germ cell tumours; 2018 NHMRC Project Grant APP1159787 ($1,587,163): BCG+MM Trial for bladder cancer; 2016 Victorian Cancer ($300,000): SCORE project on shared care of Colorectal cancer survivors; 2015 CA Priority-driven Collaborative Cancer Research Scheme ($443,307): LEAD - Lung cancer diagnostic and treatment pathways; 2015 NHMRC Project Grant 1108328 ($624,824): Oral Nicotinamide for skin cancer chemoprevention after Transplant; 2014 Co-funded Grant 1079794 ($597,095): Methoxyflurane to reduce discomfort of prostate biopsy; 2013 NHMRC Project Grant 1064121 ($880,425): CHEST Australia project for quicker primary care consultations in lung cancer; 2012 NHMRC Project Grant APP1047100 ($2,203,171): Bovine lactoferrin study on low birthweight infants; 2011 National Breast Cancer Foundation ($199,606): Physical well-being for metastatic breast cancer; 2011 NHMRC Project Grant 1028555 ($187,018): Evidence on reduced child obesity rates; 2011 NHMRC Project Grant 1026977 ($586,691): Oral nicotinamide for skin cancer prevention; 2011 Australasian College of Dermatologists grant ($25,000): Nicotinamide for non-melanoma skin cancer in renal transplant recipients; 2010 NHMRC Project Grant 1007628 ($369,208): NEU-HORIZONS study on riluzole for oxaliplatin neurotoxicity; 2010 NHMRC Project Grant 1003414 ($564,410): Phase II prostate cancer follow-up trial in primary care.

Statistical lead on the following projects receiving industry funding with USyd as administering institution: ENZARAD NCT02446444 ($12,178,000); ENZAMET NCT02446405 ($20,408,129); INTEGRATE ACTRN12612000239864 ($6,900,000); INTEGRATE IIa ACTRN12616000420448 ($22,264,248); INTEGRATE IIb NCT04879368 ($36,330,215); DASL-HiCaP NCT04136353 ($33,777,579).